Bristol Myers: 10-year strategy for poor countries
This strategy supports the pharmaceutical company's commitment to reach more than 200,000 patients in low- and middle-income countries with its innovative treatments.000 patients in low- and middle-income countries by 2033 with its innovative treatments.
In particular, Bristol Myers is entering into a strategic collaboration with the Access to Medicines in Oncology Coalition (ATOM) to expand access to its Opdivo immuno-oncology therapy in selected countries.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction